DNER and diffuse large B-cell lymphoma: Preclinical [1, 3‐9] data show that diffuse large B‐cell lymphomas (DLBCL), and in particular the activated B‐cell like (ABC) subtype, are sensitive to the treatment with BET inhibitors, although the clinical activity [1, 10‐13] has been so far rather limited.